NEW YORK and CAESAREA, Israel, March
29, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:
DRIO), a leading global digital health company with mobile health
and big data solutions, today announced it will offer its past and
current subscription holders the option to pre-order its first
Lightning®-enabled version of the acclaimed Dario™ Blood Glucose
Monitoring System in the U.S. commencing on April 16, 2018.
Subscription holders who are interested in ordering the new
device will need to place their order through DarioHealth's special
hotline for ordering: 1-888-665-7201.
DarioHealth expects to ship its first iPhone
Lightning-compatible glucose monitor in the coming weeks.
DarioHealth's vision includes simplifying diabetes management, and
with its new product, DarioHealth can now cater to most people with
diabetes in the U.S. that use smartphones.
Erez Raphael, Chairman and CEO of
DarioHealth, commented, "DarioHealth is very proud of its recent
accomplishments, including being named the Best Glucometer for Data
Management by Top Ten Reviews. This is the first time we are
conducting a pre-order and it is because of the positive feedback
and demand that we have received from our customer base. We look
forward to welcoming back past subscribers who upgraded to these
new iPhones to renew their Dario experience."
DarioHealth has been marketing the product in the U.S.
exclusively for Apple iOS 6.1 platform and higher since the FDA
first granted clearance for the Dario Blood Glucose Monitoring
System in December 2015, and certain
leading Android SMD's including Samsung Galaxy S series, Samsung
Galaxy Note series, and LG G series, since September 2017. With today's news, DarioHealth
begins expanding its U.S. marketing reach.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital
health company serving its users with dynamic mobile health
solutions. In today's day and age, knowledge of health and
treatment is being democratized, and we believe people deserve to
know everything about their own health and have the best tools to
manage their condition. DarioHealth employs a revolutionary
approach whereby harnessing big data, we have developed a novel
method for chronic disease data management, empowering people to
analyze and personalize self-diabetes management in a totally new
way without having the disease slow them down. DarioHealth has a
commercial office in New York with
an R&D center in Caesarea,
Israel. For more information, visit
http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company describes
expanding the market reach in the United
States for its products, it is using forward-looking
statements. Readers are cautioned that certain important factors
may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements
that may be made in this news release. Factors that may affect the
Company's results include, but are not limited to, regulatory
approvals, product demand, market acceptance, impact of competitive
products and prices, product development, commercialization or
technological difficulties, the success or failure of negotiations
and trade, legal, social and economic risks, and the risks
associated with the adequacy of existing cash resources. Additional
factors that could cause or contribute to differences between the
Company's actual results and forward-looking statements include,
but are not limited to, those risks discussed in the Company's
filings with the U.S. Securities and Exchange Commission. Readers
are cautioned that actual results (including, without limitation,
the timing for and results of the Company's commercial and
regulatory plans for Dario™) may differ significantly from those
set forth in the forward-looking statements. The Company undertakes
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director,
shmuel@mydario.com, +1-914-775-5548
DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, terese@rosica.com,
+1-201-843-5600
DarioHealth Investor Relations Contact: Westwicke
Partners, Dario@Westwicke.com, +1-443-213-0500
View original
content:http://www.prnewswire.com/news-releases/dariohealth-launches-customer-hotline-to-pre-order-its-apple-iphone-lightning-compatible-glucose-monitor-in-the-us-300621616.html
SOURCE DarioHealth Corp.